Abstract:OBJECTIVE:To analyze and summarize the characteristics of glycogen storage disease type II (Pompe disease) patients according to the clinical description and prognosis.METHOD:Seventeen Chinese patients diagnosed by acid alpha-glucosidase (GAA) enzyme activity test were reviewed. Clinical data tables were designed. Interviews were made via phone calls. Information was collected to reach the objective.RESULT:Four of 17 patients diagnosed by acid alpha-glucosidase are infantile-onset, symptoms started between 2 to 6 months after birth with increased serum creatine kinase and cardiac problems, with or without respiratory concerns. Other 13 patients were later-onset cases, and their symptoms started between 2 to 22 years of age with increased serum creatine kinase. Eleven later-onset patients started with muscle weakness, 2 patients developed respiratory insufficiency, 2 patients showed scoliosis, and 1 patient expressed increased serum creatine kinase with abnormal liver function. Just 3 of the later-onset patients were treated with mechanical ventilator and adjuvant therapy, others were not. All patients' acid alpha-glucosidase (GAA) enzyme activity analysis showed lower than 10% of normal. Fourteen patients were tested by muscle biopsy pathology, and 9 of them progressed to glycogen storage disease type II; 10 patients received genetic analysis, and 6 of them had two mutations which cause the disorder. Twelve of the 17 patients were interviewed successfully. In 3 of the infant-onset patients the disease resulted in death from respiratory failure, and 1 is still alive at the age of 1 year and 7 months. In 4 of 8 later-onset patients the disease resulted in death from respiratory failure between 3 to 5 years after onset of symptoms. Three of 4 survivors had increased muscle weakness, and 1 patient kept alive with ventilator without any changes. Seven of 12 interviewed patients died, the mortality rate was 58.3%.CONCLUSION:Glycogen storage disease type II (Pompe disease) present differently in the clinic. Infant-onset Pompe disease is mainly characterized by generalized muscle weakness and obvious cardiac involvement. It's a dangerous disease, with high mortality rate. Later-onset Pompe disease is characterized by chronic proximal muscle weakness and respiratory insufficiency. GAA enzyme activity analysis, muscle biopsy and genetic analysis used to support the diagnosis of Pompe disease. Prognosis of the disease depends on age of onset and respiratory muscle involvement.

The 81st case:a 58 years old male patient presented with later motor milestone, frequent falling for 55 years, weakness of lower limbs for 13 years, upper limbs weakness for 3 years

The Novel Compound Heterozygous Mutations in the AGL Gene in a Chinese Family With Adult Late-Onset Glycogen Storage Disease Type IIIa

[Clinical and Gene Mutation Analysis of Three Children with Late-Onset Glycogen Storage Disease Type Ⅱ with Hypertrophic Cardiomyopathy].

Clinical and Pathological Features of Late-onset Glycogen Storage Disease Type Ⅱ

A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III

Glycogen Storage Disease Type Ⅱ: 2 Cases Report and Literature Review

[The Clinical and Pathological Characteristics of a Patient with Glycogen Storage Disease IV].

Congenital Disorder of Glycosylation Type 1T with a Novel Truncated Homozygous Mutation in PGM1 Gene and Literature Review.

Genetic Analysis and Clinical Assessment of Four Patients with Glycogen Storage Disease Type IIIa in China

Genetic analysis and long-term treatment monitoring of 11 children with glycogen storage disease type IIIa

P.17.12 POLG mitochondrial myopathy presenting as a limb girdle syndrome

Lipid-storage myopathy with glycogen storage disease gene mutations mimicking polymyositis: a case report and review of the literature

[Infant glycogen storage disease type Ⅳ: a clinicopathological and genetic characteristics analysis of five cases]

[Clinical Features and Acid Alpha-Glucosidase Gene Mutation in 7 Chinese Patients with Glycogen Storage Disease Type II].

A Novel Mutation in GNE Gene: Clinical Characteristics and Bioinformatics Analysis

Clinical and Functional Characterization of Novel AGL Variants in Two Families with Glycogen Storage Disease Type III

A case report on multiple acyl-CoA dehydrogenase deficiency with severe myopathy and osteoporosis

Unusual presentation of PYGM gene mutation as late-onset McArdle disease with camptocormia: a case report

[Clinical Sequelae of 17 Cases with Glycogen Storage Disease Type II/Pompe Disease].

Expanding the clinicopathological-genetic spectrum of glycogen storage disease type IXd by a Chinese neuromuscular center

Molecular Genetic Analysis of 10 Chinese Patients with Glycogen Storage Disease Type Iii